We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Simple Blood Test Measures Thyroxine Levels

By HospiMedica staff writers
Posted on 07 Aug 2007
A fast and accurate test has been developed to measure thyroxine, the major hormone released by the thyroid gland.

The new mass spectrometry test measures the thyroxine molecule specifically and uses a filtering system to separate out the free thyroxine--the form that is active--from deactivated thyroxine that is bound to proteins. More...
The test was developed by Steven Soldin, Ph.D. FACB, professor at Georgetown University Medical Center (GUMC; Washington, DC, USA).

When the thyroid gland produces too little thyroxine, the condition is known as hypothyroidism, whereas when the gland produces too much, the condition is called hyperthyroidism. Thyroxine regulates the body's metabolism, and hypothyroidism, associated with fatigue and weight gain, is much more common than hyperthyroidism, which is characterized by weight loss.

In order to treat these conditions, physicians need to know how much synthetic thyroxine to either give patients or how much natural hormone should be blocked, and there have long been concerns that the common immunoassay test now in use worldwide is neither specific nor very accurate. To date, the immunoassay test has been used to measure those levels in women known to have abnormal levels of thyroid function based on a screening test.

In a study initiated by the Georgetown University scientists, investigators tested the method they had developed and found that it was far superior to the currently used immunoassay and just as good as an expensive, time-consuming, but very accurate laboratory analysis that is less commonly used. The scientists estimated the ability of their new test to measure thyroxine in blood donated by two groups of women: a group of 98 pregnant women and a control group of 29 women who were not pregnant. Measuring the hormone in pregnant women can be problematic because some conditions (e.g., high levels of binding proteins and certain antibodies) affect immunoassay performance.

Three different tests were used in the study--the immunoassay, the Georgetown tandem mass spectrometry, and the "gold standard” laboratory test known as equilibrium dialysis--to measure the hormone in blood samples donated by the women. They found that, across all stages of pregnancy, there was almost total agreement between mass spectrometry and equilibrium dialysis, but immunoassay results differed significantly.

Thyroxine output dramatically changes during pregnancy in order to support development of the fetus. The hormone helps control metabolism and physical development, and because a fetus does not develop its own supply until the second trimester, it is crucial that pregnant women have adequate supplies in the first trimester.

One major use of such a test would be to help guide treatment of people with hypothyroidism or hyperthyroidism. Physicians diagnose these conditions using a test that measures thyroid-stimulating hormone (TSH), a hormone released by the pituitary gland, which stimulates the thyroid gland to secrete thyroxine. When TSH is high, levels of thyroxine are low, and vice versa.

After the condition is diagnosed, doctors use the immunoassay to determine what level of thyroxine should be supplemented or repressed. "We think our treatment of hyperthyroidism and hypothyroidism would be much more accurate if we combined TSH testing with tandem mass spectrometry instead of with the immunoassay,” said one of the study's investigators, Jacqueline Jonklaas, M.D., Ph.D


Related Links:
Georgetown University Medical Center

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.